Free Trial

ARS Pharmaceuticals (SPRY) Competitors

ARS Pharmaceuticals logo
$16.95 -0.14 (-0.82%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$16.94 -0.01 (-0.06%)
As of 07/8/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SPRY vs. RVMD, LEGN, GRFS, TGTX, LNTH, NUVL, TLX, AXSM, ADMA, and AKRO

Should you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Lantheus (LNTH), Nuvalent (NUVL), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), ADMA Biologics (ADMA), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry.

ARS Pharmaceuticals vs. Its Competitors

ARS Pharmaceuticals (NASDAQ:SPRY) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

ARS Pharmaceuticals has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.

ARS Pharmaceuticals currently has a consensus target price of $31.00, suggesting a potential upside of 82.89%. Revolution Medicines has a consensus target price of $68.00, suggesting a potential upside of 86.61%. Given Revolution Medicines' higher probable upside, analysts clearly believe Revolution Medicines is more favorable than ARS Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ARS Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17
Revolution Medicines
0 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
3.00

ARS Pharmaceuticals has higher revenue and earnings than Revolution Medicines. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ARS Pharmaceuticals$89.15M18.67$8M-$0.16-105.94
Revolution Medicines$11.58M586.16-$600.09M-$4.00-9.11

Revolution Medicines has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -16.11%. ARS Pharmaceuticals' return on equity of -6.94% beat Revolution Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
ARS Pharmaceuticals-16.11% -6.94% -5.60%
Revolution Medicines N/A -37.06%-32.84%

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 33.5% of ARS Pharmaceuticals shares are held by insiders. Comparatively, 8.2% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Revolution Medicines had 3 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 9 mentions for Revolution Medicines and 6 mentions for ARS Pharmaceuticals. Revolution Medicines' average media sentiment score of 1.07 beat ARS Pharmaceuticals' score of 0.83 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ARS Pharmaceuticals
4 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Revolution Medicines
4 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Revolution Medicines beats ARS Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get ARS Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPRY vs. The Competition

MetricARS PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.68B$2.39B$5.47B$8.95B
Dividend YieldN/A1.80%5.25%4.06%
P/E Ratio-105.938.9827.0020.10
Price / Sales18.67729.50435.75120.29
Price / Cash2,018.11159.8036.8257.86
Price / Book6.424.517.985.56
Net Income$8M$31.26M$3.16B$248.40M
7 Day Performance5.34%5.57%3.69%6.04%
1 Month Performance16.98%5.48%2.91%7.69%
1 Year Performance78.80%1.14%34.30%20.97%

ARS Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPRY
ARS Pharmaceuticals
3.2327 of 5 stars
$16.95
-0.8%
$31.00
+82.9%
+78.8%$1.68B$89.15M-105.9390Gap Up
RVMD
Revolution Medicines
4.5646 of 5 stars
$36.79
-0.3%
$67.58
+83.7%
-7.9%$6.85B$11.58M-9.20250Positive News
LEGN
Legend Biotech
3.0504 of 5 stars
$35.49
+2.5%
$76.20
+114.7%
-20.9%$6.52B$627.24M-60.152,609Positive News
Analyst Forecast
GRFS
Grifols
4.0825 of 5 stars
$9.04
+2.0%
$10.30
+13.9%
+7.0%$6.22B$7.81B7.7323,822News Coverage
Analyst Upgrade
TGTX
TG Therapeutics
3.89 of 5 stars
$35.99
-2.0%
$40.80
+13.4%
+82.1%$5.71B$386.39M149.96290News Coverage
Positive News
LNTH
Lantheus
4.4152 of 5 stars
$81.86
+0.5%
$130.50
+59.4%
+4.6%$5.66B$1.53B23.26700
NUVL
Nuvalent
3.7406 of 5 stars
$76.30
-4.2%
$119.60
+56.7%
+8.9%$5.48BN/A-17.3840
TLX
Telix Pharmaceuticals
N/A$16.07
+0.4%
$22.00
+36.9%
N/A$5.44B$516.72M0.00N/A
AXSM
Axsome Therapeutics
4.7718 of 5 stars
$104.39
+1.0%
$172.33
+65.1%
+29.6%$5.14B$432.16M-18.09380
ADMA
ADMA Biologics
4.1295 of 5 stars
$18.21
+0.3%
$27.67
+51.9%
+53.0%$4.35B$426.45M21.42530Positive News
AKRO
Akero Therapeutics
3.4365 of 5 stars
$53.36
-5.0%
$82.50
+54.6%
+127.0%$4.25BN/A-27.3630

Related Companies and Tools


This page (NASDAQ:SPRY) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners